ArticleFrontiers in bioengineering and biotechnology2026
Evidence architecture of glaucoma-related biomaterials reveals an uneven transition toward smart materials, additive manufacturing, and functional tissue engineering.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glaucoma-related biomaterial research has expanded from ocular drug delivery to responsive hydrogels, anti-fibrotic systems, glaucoma drainage device (GDD) and minimally invasive glaucoma surgery (MIGS)-related interfaces, retinal ganglion cell protection, trabecular meshwork models, and additive manufacturing. Whether this expansion represents a coherent transition toward smart, manufacturable, and function-oriented tissue-engineering systems remains unclear. Methods: We conducted an AI-assisted, rule-guided, and manually audited evidence architecture reconstruction of glaucoma-related biomaterial studies published from 2006 to 2025. Records from Web of Science Core Collection, Scopus, and PubMed were integrated, deduplicated, parsed from RIS files, screened, and quality controlled. Retained studies were classified by application scenario, evidence level, and translational features. Core evidence records were assigned to five operational levels, from material preparation and physicochemical characterization to disease-microenvironment intervention, long-term functional integration, and clinical or advanced translational evidence. Theme maturity and the convergence of smart material, additive manufacturing, and tissue-engineering relevance were further assessed. Results: From 1,227 parsed records, 596 were retained, including 547 core evidence studies and 49 review or background records. In the core evidence set, Level 1 to Level 5 evidence included 93, 57, 140, 99, and 158 records, respectively. Level 1-3 evidence accounted for 53.0% of the core evidence set, whereas Level 4-5 evidence accounted for 47.0%, indicating a substantial but unevenly distributed translational component. Conclusion: Glaucoma-related biomaterials are moving beyond passive delivery platforms, but their transition toward smart materials, additive manufacturing, and functional tissue engineering remains uneven. Future studies should emphasize reproducible material design, disease-relevant functional endpoints, outflow-pathway models, neuroprotection, and engineered surgical interfaces.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.